| Name | 8-[(2,6-dimethylphenyl)methylamino]-N-(2-hydroxyethyl)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide |
|---|---|
| Synonyms |
Linaprazan [INN:BAN]
UNII-E0OU4SC8DP AZD0865 Linaprazan |
| Description | AZD0865 inhibits gastric H+,K+-ATPase by K+-competitive binding. (IC50: 1.0 ± 0.2 μM)It is a acid-suppressing agents with rapid onset of action and potent acid inhibition. In vitro: AZD0865 can inhibit the final step in acid secretion. AZD0865 reduced porcine renal Na+,K+-ATPase activity by 9 ± 2%, demonstrating a high selectivity for H+,K+-ATPase.In vivo: The reference for animal administration is 0.5-1.0 mg/kg. The greater degree of acid suppression with the 75-mg dose of AZD0865 would translate to a healing rate of 89% at 4 weeks. |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C21H26N4O2 |
|---|---|
| Molecular Weight | 366.45700 |
| Exact Mass | 366.20600 |
| PSA | 82.15000 |
| LogP | 3.54990 |